Citizens upgrades Quince Therapeutics to Market Outperform, $77 target
Citizens upgraded Quince Therapeutics to Market Outperform and set a $77.00 price target, implying 148.4% upside from the Sep 21 close of $31.00.
00. 4% from the Sep 21 close of $31. The analyst note cited recent encouraging Phase 2a clinical data from Quince Therapeutics.